Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1130-1140

  Totani, Licia ^a   Dell'Elba, Giuseppe ^a   Martelli, Nicola ^a   di Santo, Angelomaria ^a   Piccoli, Antonio ^a   Amore, Concetta ^a   Evangelista, Virgilio ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Inflammation; Monocytes; Neutrophils; P selectin; Platelets; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CD11B ANTIGEN; DRUG METABOLITE; FIBRINOGEN RECEPTOR; INTERLEUKIN 1BETA; NITRIC OXIDE; PADGEM PROTEIN; PLACEBO; PRASUGREL; R 138727 METABOLITE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPTIC SHOCK; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PIPERAZINES; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SELENOPROTEIN P; SHOCK, SEPTIC; THIOPHENES; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861719794     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-12-0867     Document Type: Article

References (35)

1. Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct anti-platelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
2. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
4. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
5. Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-1205.
6. Mickelson JK, Lakkis NM, Villarreal-Levy G, et al. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol 1996; 28: 345-353.
7. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
8. Massberg S, Brand K, Grüner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
9. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice but not P-se-lectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation 2001; 103: 2501-2507.
10. Evangelista V, Manarini S, Sideri R, et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-885.
11. Evangelista V, Pamuklar Z, Piccoli A, et al. Src family kinases mediate neutrophil adhesion to adherent platelets. Blood 2007; 109: 2461-2469.
12. Weyrich AS, Elstad MR, McEver R P, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-1534.
13. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387-2394.
14. Dixon DA, Tolley ND, Bemis-Standoli K, et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 2006; 116: 2727-2738.
15. Niemetz J, Marcus AJ. The stimulatory effect of platelets and platelet membranes on the procoagulant activity of leukocytes. J Clin Invest 1974; 54: 1437-1443.
16. Di Santo A, Amore C, Dell'Elba G, et al. Glycogen synthase kinase-3 negatively regulates tissue factor expression in monocytes interacting with activated platelets. J Thromb Haemost 2011; 9: 1029-1039.
17. Storey RF, Judge HM, Wilcox RG, et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by prasugrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.
18. Klinkhardt U, Bauersachs R, Adams J, et al. Prasugrel but not aspirin reduces P-se-lectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-241.
19. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.
20. Leon C, Alex M, Klocke A, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004; 103: 594-600.
21. Evangelista V, Manarini S, Dell'Elba G, et al. Clopidogrel Inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
22. Frelinger AL, Jakubowski JA, Li Y, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008;6: 359-365.
23. Braun OO, Johnell M, Varenhorst C, et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633.
24. Von Hundelshausen P, Weber C. Platelets as immune cells: Bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
25. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
26. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
27. Steinhubl SR, Badimon JJ, Bhatt DL, et al. Clinical ev idence for anti-inflammator y effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-122.
28. Frelinger III AL, Jakubowski JA, Li YF, et al. The active metabolite of prasugrel inhibits ADP-stimulated thromboinflammatory markers of platelet activation: Influence of other blood cells, calcium and aspirin. Thromb Haemost 2007; 98: 192-200.
29. Smyth SS, Woulfe DS, Weitz JI, et al. G-protein-coupled receptors as signaling targets for anti-platelet therapy. Arterioscler Thromb Vasc Biol 2009; 29: 449-457.
30. Woulfe D, Jiang H, Morgans A, et al. Dfects in secrtetion, aggregation and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004; 113: 441-450.
31. Kim S, Jin J, Kunapuli S P. Akt activation in platelets depends on Gi signalling pathways. J Biol Chem 2004; 279: 4186-4195.
32. Garcia A, Kim S, Bhavaraju K, et al. Role of phosphoinositide 3-kinsae b in platelet aggregation and thromboxane A2 generation m edi ated by Gisi gnal ling pat hways. Biochem J 2010; 429: 369-377.
33. Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccaride-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 2006; 107: 637-641.
34. Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-2423.
35. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007; 13: 463-469.